Equities research analysts predict that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will announce $3.80 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for BioCryst Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $3.20 million and the highest estimate coming in at $4.10 million. BioCryst Pharmaceuticals posted sales of $3.10 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 22.6%. The firm is expected to issue its next earnings results on Monday, August 6th.
According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full year sales of $19.78 million for the current financial year, with estimates ranging from $16.75 million to $21.77 million. For the next year, analysts anticipate that the firm will post sales of $21.37 million per share, with estimates ranging from $19.02 million to $24.40 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow BioCryst Pharmaceuticals.
Get BioCryst Pharmaceuticals alerts:
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.10). BioCryst Pharmaceuticals had a negative return on equity of 114.36% and a negative net margin of 392.09%. The firm had revenue of $3.98 million for the quarter, compared to analysts’ expectations of $10.20 million.
BCRX has been the subject of several research reports. BidaskClub raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 4th. Zacks Investment Research raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research report on Tuesday, May 1st. ValuEngine raised shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 14th. Seaport Global Securities reissued a “neutral” rating on shares of BioCryst Pharmaceuticals in a research report on Thursday, June 28th. Finally, Bank of America raised shares of BioCryst Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research report on Tuesday, July 17th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. BioCryst Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $8.36.
In other BioCryst Pharmaceuticals news, CMO William P. Sheridan sold 42,112 shares of the business’s stock in a transaction dated Friday, June 1st. The shares were sold at an average price of $6.30, for a total value of $265,305.60. Following the completion of the sale, the chief marketing officer now directly owns 63,170 shares of the company’s stock, valued at approximately $397,971. The transaction was disclosed in a filing with the SEC, which is available through this link. 5.21% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently made changes to their positions in BCRX. Schwab Charles Investment Management Inc. lifted its position in shares of BioCryst Pharmaceuticals by 55.2% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 496,792 shares of the biotechnology company’s stock worth $2,440,000 after purchasing an additional 176,714 shares during the period. Teacher Retirement System of Texas purchased a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth approximately $155,000. The Manufacturers Life Insurance Company lifted its position in shares of BioCryst Pharmaceuticals by 21.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 76,741 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 13,760 shares during the period. Bank of New York Mellon Corp lifted its position in shares of BioCryst Pharmaceuticals by 25.4% in the 4th quarter. Bank of New York Mellon Corp now owns 464,191 shares of the biotechnology company’s stock worth $2,279,000 after purchasing an additional 94,160 shares during the period. Finally, BlackRock Inc. lifted its position in shares of BioCryst Pharmaceuticals by 15.0% in the 4th quarter. BlackRock Inc. now owns 7,614,280 shares of the biotechnology company’s stock worth $37,386,000 after purchasing an additional 993,100 shares during the period. 89.91% of the stock is owned by hedge funds and other institutional investors.
BioCryst Pharmaceuticals traded down $0.12, hitting $5.94, during trading hours on Tuesday, MarketBeat.com reports. The company had a trading volume of 321,676 shares, compared to its average volume of 710,194. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.38 and a quick ratio of 1.38. BioCryst Pharmaceuticals has a 1 year low of $3.95 and a 1 year high of $6.69.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Featured Story: Earnings Per Share
Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com